Clinical Trial Update: Immune Response of Individuals Vaccinated With Hypoallergenic Derivatives of the Major Birch Pollen Allergen, Bet v 1 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating immune response to hypoallergenic derivatives of Bet v 1, the major birch pollen allergen.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Birch Pollen Allergy

Drugs mentioned

• Hypoallergenic derivatives of Bet v 1

Snippet

Sponsor: Medical University of Vienna | Conditions: Allergy | Phase 1 | Status: UNKNOWN